Effects of bone turnover status on the efficacy and safety of denosumab among haemodialysis patients

Mayuko Hori, Kaoru Yasuda, Hiroshi Takahashi, Chika Kondo, Yuichi Shirasawa, Yuka Ishimaru, Yuka Sekiya, Kunio Morozumi, Shoichi Maruyama

Research output: Contribution to journalArticlepeer-review


Denosumab is reported to increase bone mineral density (BMD) among haemodialysis patients; however, hypocalcaemia is a serious adverse effect among chronic kidney disease (CKD) patients. Identifying which patients will show greater improvement in BMD is important. We enrolled 84 haemodialysis patients with osteoporosis in our study. 28 patients initiated denosumab treatment between October 2019 and October 2020. We assessed BMD changes and investigated the association between baseline bone turnover marker (BTM) levels and 6-month changes in BMD after denosumab treatment. BMD was increased at 6 months in denosumab-treated patients compared with patients not treated with denosumab (lumbar spine: 5.34% vs. − 0.49%; total hip: 2.43% vs. − 0.47%). Bone-specific alkaline phosphatase (BAP) and tartrate-resistant acid phosphatase-5b (TRACP-5b) at baseline were independently associated with increased BMD in the total hip (BAP: β = 0.472, p value = 0.004; TRACP-5b: β = 0.433, p value = 0.008) and lumbar spine (BAP: β = 0.591, p value = 0.001; TRACP-5b: β = 0.613, p value = 0.0008). BAP and TRACP-5b were also independent predictors of hypocalcaemic events (OR [95% CI] 1.747 [1.084–4.604] and 1.006 [1.000–1.015], respectively). BTMs may be associated with increased BMD and hypocalcaemic events after denosumab treatment. BTM measurement may be useful for assessing the effect of denosumab on BMD; however, careful monitoring of serum calcium levels is needed.

Original languageEnglish
Article number7781
JournalScientific reports
Issue number1
Publication statusPublished - 12-2022
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • General


Dive into the research topics of 'Effects of bone turnover status on the efficacy and safety of denosumab among haemodialysis patients'. Together they form a unique fingerprint.

Cite this